Risk and protective effects of the APOE gene towards Alzheimer's disease in the Kungsholmen project: variation by age and sex
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The risk effect of APOE epsilon 4 allele for Alzheimer's disease is acknowledged, whereas the putative protective effect of epsilon 2 allele remains in debate. OBJECTIVES: To investigate whether those inconsistent findings may be attributable to differences in age and sex composition of the study populations. METHODS: A community dementia free cohort (n = 985) aged > or =75 years was followed up to detect Alzheimer's disease cases (DSM-III-R criteria). Data were analysed using Cox models with adjustment for major potential confounders. RESULTS: Over a median 5.6 year follow up, Alzheimer's disease was diagnosed in 206 subjects. Compared with APOE epsilon 3/epsilon 3 genotype, the relative risk (RR) of Alzheimer's disease was 1.4 (95% confidence interval (CI), 1.0 to 2.0; p = 0.03) for heterozygous epsilon 4 allele and 3.1 (95% CI, 1.6 to 5.9) for homozygous epsilon 4 allele. The association between epsilon 4 allele and Alzheimer's disease risk was stronger in men than in women (RR related to the interaction term epsilon 4 allele by sex, 0.4; 95% CI, 0.2 to 0.9). The epsilon 4 allele accounted for one third of Alzheimer's disease cases among men, but only one tenth among women. The epsilon 2 allele was related to a reduced Alzheimer's disease risk mainly in people aged <85 years (RR, 0.4; 95% CI, 0.2 to 0.8). The RR of Alzheimer's disease related to the interaction term of epsilon 2 allele by age was 2.4 (95% CI, 1.0 to 6.0; p = 0.06). CONCLUSIONS: The APOE genotype specific effects on Alzheimer's disease vary by age and sex, in which the epsilon 4 allele has a stronger risk effect in men, and the epsilon 2 allele confers a protective effect only in younger-old people.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
Dementia and Alzheimer Disease Incidence: A Prospective Cohort Study
Kukull, W. A., Higdon, R., Bowen, J. D., McCormick, W. C., Teri, L., Schellenberg, G. D., van Belle, G., Jolley, L., & Larson, E. B. (2002) · Archives of Neurology · doi:10.1001/archneur.59.11.1737 · Cited by 806
Tang, M.-X. (1998) · JAMA · doi:10.1001/jama.279.10.751 · Cited by 771
Fratiglioni, L., Viitanen, M., von Strauss, E., Tontodonati, V., Herlitz, A., & Winblad, B. (1997) · Neurology · doi:10.1212/wnl.48.1.132 · Cited by 556
Self-citationApolipoprotein E, Dementia, and Cortical Deposition of β-Amyloid Protein
Polvikoski, T., Sulkava, R., Haltia, M., Kainulainen, K., Vuorio, A., Verkkoniemi, A., Niinistö, L., Halonen, P., & Kontula, K. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511093331902 · Cited by 493
Slooter, A. J. C., Cruts, M., Kalmijn, S., Hofman, A., Breteler, M. M. B., Van Broeckhoven, C., & van Duijn, C. M. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.964 · Cited by 399
Evans, D. A., Bennett, D. A., Wilson, R. S., Bienias, J. L., Morris, M. C., Scherr, P. A., Hebert, L. E., Aggarwal, N., Beckett, L. A., Joglekar, R., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.2.185 · Cited by 370
Farrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124
Gender and age modify the association between APOE and AD-related neuropathology
Ghebremedhin, E., Schultz, C., Thal, D. R., Rüb, U., Ohm, T. G., Braak, E., & Braak, H. (2001) · Neurology · doi:10.1212/wnl.56.12.1696 · Cited by 108
APOE ε4 does not predict mortality, cognitive decline, or dementia in the oldest old
Juva, K., Verkkoniemi, A., Viramo, P., Polvikoski, T., Kainulainen, K., Kontula, K., & Sulkava, R. (2000) · Neurology · doi:10.1212/wnl.54.2.412 · Cited by 108
Cited by
Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention
Qiu, C., Kivipelto, M., & von Strauss, E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/cqiu · Cited by 1,261
“The risk effect of APOE ε4 allele on AD decreases with increasing age, and overall approximately 15% to 20% of Alzheimer cases are attributable to the ε4 allele.(39,42) Several other candidate genes, many of them vascular related such as angiotensin-I converting enzyme, cholesterol 24-hydroxylase, and insulin-degradin…”
BackgroundSelf-citationAge, APOE and sex: triad of risk of Alzheimer’s disease.
Riedel, B. C., Thompson, P. M., & Brinton, R. D. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.03.012 · Cited by 627
Goldman, J. S., Hahn, S. E., Catania, J. W., Larusse-Eckert, S., Butson, M. B., Rumbaugh, M., Strecker, M. N., Roberts, J. S., Burke, W., Mayeux, R., et al. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e31821d69b8 · Cited by 393
Genetic epidemiology and public health: hope, hype, and future prospects
Smith, G. D., Ebrahim, S., Lewis, S., Hansell, A. L., Palmer, L. J., & Burton, P. R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67601-5 · Cited by 300
Apolipoprotein E–dependent accumulation of Alzheimer disease–related lesions begins in middle age
Kok, E., Haikonen, S., Luoto, T., Huhtala, H., Goebeler, S., Haapasalo, H., & Karhunen, P. J. (2009) · Annals of Neurology · doi:10.1002/ana.21696 · Cited by 299
Sando, S. B., Melquist, S., Cannon, A., Hutton, M. L., Sletvold, O., Saltvedt, I., White, L. R., Lydersen, S., & Aasly, J. O. (2008) · BMC Neurology · doi:10.1186/1471-2377-8-9 · Cited by 261
“While smaller studies in this field have been published from Norway, to our knowledge this is the first report of APOE allele frequencies and APOE genotypes in a large Norwegian AD population and the largest study on APOE allele frequencies in AD patients from Scandinavia to date.”
BackgroundAccelerated Progression From Mild Cognitive Impairment to Dementia in People With Diabetes
Xu, W., Caracciolo, B., Wang, H.-X., Winblad, B., Bäckman, L., Qiu, C., & Fratiglioni, L. (2010) · Diabetes · doi:10.2337/db10-0539 · Cited by 260
“Genomic DNA was prepared from peripheral blood samples that were taken at baseline, and APOE allelic status was determined following a standard procedure (28).”
MethodSelf-citationShaw, P., Lerch, J. P., Pruessner, J. C., Taylor, K. N., Rose, A. B., Greenstein, D., Clasen, L., Evans, A., Rapoport, J. L., & Giedd, J. N. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70106-0 · Cited by 257
APOE alleles predict the rate of cognitive decline in Alzheimer disease: A nonlinear model
Martins, C. A. R., Oulhaj, A., de Jager, C. A., & Williams, J. H. (2005) · Neurology · doi:10.1212/01.wnl.0000188871.74093.12 · Cited by 205
Cardiovascular Risk Factors and Incident Alzheimer Disease: A Systematic Review of the Literature
Purnell, C., Gao, S., Callahan, C. M., & Hendrie, H. C. (2009) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318187541c · Cited by 189
“The third paper from the Kungsholmen Project reported that APOE e2 also did not affect risk in a Swedish population except in females between the ages of 75 and 84.(64) In this segment of the population, the presence of APOE e2 decreased risk significantly.”
BackgroundQian, J., Wolters, F. J., Beiser, A., Haan, M., Ikram, M. A., Karlawish, J., Langbaum, J. B., Neuhaus, J. M., Reiman, E. M., Roberts, J. S., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002254 · Cited by 169
Reduction of optic nerve fibers in patients with Alzheimer disease identified by laser imaging
Danesh-Meyer, H. V., Birch, H., Ku, J. Y.-F., Carroll, S., & Gamble, G. (2006) · Neurology · doi:10.1212/01.wnl.0000244490.07925.8b · Cited by 164
Keeney, J. T.-R., Ibrahimi, S., & Zhao, L. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150348 · Cited by 102
APOE2 orchestrated differences in transcriptomic and lipidomic profiles of postmortem AD brain
Lefterov, I., Wolfe, C. M., Fitz, N. F., Nam, K. N., Letronne, F., Biedrzycki, R. J., Kofler, J., Han, X., Wang, J., Schug, J., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0558-0 · Cited by 74
Cerebrovascular degradation of TRKB by MMP9 in the diabetic brain
Navaratna, D., Fan, X., Leung, W., Lok, J., Guo, S., Xing, C., Wang, X., & Lo, E. H. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65767 · Cited by 32
Age stratification corrects bias in estimated hazard of APOE genotype for Alzheimer's disease
Liu, L., & Caselli, R. J. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.09.006 · Cited by 29
“contradictory findings that vary from higher risk to lower risk in women to no difference between the sexes [1,2,10].”
BackgroundHan, F., Xu, H., Shen, J.-X., Pan, C., Yu, Z.-H., Chen, J.-J., Zhu, X.-L., Cai, Y.-F., & Lu, Y.-P. (2020) · Acta Neurobiologiae Experimentalis · doi:10.21307/ane-2020-021 · Cited by 18
“It has been proposed that the com‐ bined effect of multiple factors is the most likely cause of AD formation, especially for sAD (Farrer et al., 1997; Qiu et al., 2004; Seripa et al., 2009; Wyss‐Coray and Rog‐ ers, 2012; Orsucci et al., 2013; Solomon et al., 2014).”
Background
Metadata
- Authors
- Qiu, C.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2004-06-01
- Volume
- 75
- Issue
- 6
- Pages
- 828-833
- ISSN
- 0022-3050 (ISSN-L)
- OpenAlex
- W2005010859
- Cited by
- 110
- References
- 10
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.